Literature DB >> 29845679

Concise Review: Prostate Cancer Stem Cells: Current Understanding.

Sergej Skvortsov1,2, Ira-Ida Skvortsova1,2, Dean G Tang3,4, Anna Dubrovska5.   

Abstract

Prostate cancer (PCa) is heterogeneous, harboring phenotypically diverse cancer cell types. PCa cell heterogeneity is caused by genomic instability that leads to the clonal competition and evolution of the cancer genome and by epigenetic mechanisms that result in subclonal cellular differentiation. The process of tumor cell differentiation is initiated from a population of prostate cancer stem cells (PCSCs) that possess many phenotypic and functional properties of normal stem cells. Since the initial reports on PCSCs in 2005, there has been much effort to elucidate their biological properties, including unique metabolic characteristics. In this Review, we discuss the current methods for PCSC enrichment and analysis, the hallmarks of PCSC metabolism, and the role of PCSCs in tumor progression. Stem Cells 2018;36:1457-1474. © AlphaMed Press 2018.

Entities:  

Keywords:  Cancer; Cancer stem cells; Heterogeneity; Metabolism; Prostate

Mesh：

Year:  2018        PMID： 29845679      PMCID： PMC7903656          DOI： 10.1002/stem.2859

Source DB:  PubMed          Journal:  Stem Cells        ISSN： 1066-5099            Impact factor:   6.277


  256 in total

1.  Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple-Negative Breast Cancer.

Authors:  Justin D Lathia; Ofer Reizes; Praveena S Thiagarajan; Masahiro Hitomi; James S Hale; Alvaro G Alvarado; Balint Otvos; Maksim Sinyuk; Kevin Stoltz; Andrew Wiechert; Erin Mulkearns-Hubert; Awad Jarrar; Qiao Zheng; Dustin Thomas; Thomas Egelhoff; Jeremy N Rich; Huiping Liu
Journal:  Stem Cells       Date:  2015-05-15       Impact factor: 6.277

2.  Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer.

Authors:  Markus Germann; Antoinette Wetterwald; Natalia Guzmán-Ramirez; Gabri van der Pluijm; Zoran Culig; Marco G Cecchini; Elizabeth D Williams; George N Thalmann
Journal:  Stem Cells       Date:  2012-06       Impact factor: 6.277

3.  An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells.

Authors:  Claudia Peitzsch; Monica Cojoc; Linda Hein; Ina Kurth; Katrin Mäbert; Franziska Trautmann; Barbara Klink; Evelin Schröck; Manfred P Wirth; Mechthild Krause; Eduard A Stakhovsky; Gennady D Telegeev; Vladimir Novotny; Marieta Toma; Michael Muders; Gustavo B Baretton; Fiona M Frame; Norman J Maitland; Michael Baumann; Anna Dubrovska
Journal:  Cancer Res       Date:  2016-03-16       Impact factor: 12.701

4.  Combined genome and transcriptome analysis of single disseminated cancer cells from bone marrow of prostate cancer patients reveals unexpected transcriptomes.

Authors:  Miodrag Gužvić; Bernhard Braun; Roman Ganzer; Maximilian Burger; Michael Nerlich; Sebastian Winkler; Melanie Werner-Klein; Zbigniew T Czyż; Bernhard Polzer; Christoph A Klein
Journal:  Cancer Res       Date:  2014-10-15       Impact factor: 12.701

5.  Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.

Authors:  Eva Corey; Lisha G Brown; Janna E Quinn; Martin Poot; Martine P Roudier; Celestia S Higano; Robert L Vessella
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

6.  Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer.

Authors:  Xin Chen; Qiuhui Li; Xin Liu; Can Liu; Ruifang Liu; Kiera Rycaj; Dingxiao Zhang; Bigang Liu; Collene Jeter; Tammy Calhoun-Davis; Kevin Lin; Yue Lu; Hsueh-Ping Chao; Jianjun Shen; Dean G Tang
Journal:  Clin Cancer Res       Date:  2016-04-08       Impact factor: 12.531

Review 7.  MYC-induced cancer cell energy metabolism and therapeutic opportunities.

Authors:  Chi V Dang; Anne Le; Ping Gao
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

Review 8.  Aldehyde dehydrogenases in cellular responses to oxidative/electrophilic stress.

Authors:  Surendra Singh; Chad Brocker; Vindhya Koppaka; Ying Chen; Brian C Jackson; Akiko Matsumoto; David C Thompson; Vasilis Vasiliou
Journal:  Free Radic Biol Med       Date:  2012-11-27       Impact factor: 7.376

9.  A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy.

Authors:  Nelma Pertega-Gomes; Sergio Felisbino; Charlie E Massie; Jose R Vizcaino; Ricardo Coelho; Chiranjeevi Sandi; Susana Simoes-Sousa; Sarah Jurmeister; Antonio Ramos-Montoya; Mohammad Asim; Maxine Tran; Elsa Oliveira; Alexandre Lobo da Cunha; Valdemar Maximo; Fatima Baltazar; David E Neal; Lee G D Fryer
Journal:  J Pathol       Date:  2015-08       Impact factor: 7.996

10.  A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy.

Authors:  Tohru Nakagawa; Thomas M Kollmeyer; Bruce W Morlan; S Keith Anderson; Eric J Bergstralh; Brian J Davis; Yan W Asmann; George G Klee; Karla V Ballman; Robert B Jenkins
Journal:  PLoS One       Date:  2008-05-28       Impact factor: 3.240
View more
  33 in total

1.  Genetic and pharmacological inhibition of acid ceramidase prevents asymmetric cell division by neosis.

Authors:  Shai White-Gilbertson; Ping Lu; James S Norris; Christina Voelkel-Johnson
Journal:  J Lipid Res       Date:  2019-04-15       Impact factor: 5.922

2.  The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.

Authors:  Michelle Shen; Shiqin Liu; Tanya Stoyanova
Journal:  Am J Clin Exp Urol       Date:  2021-02-15

Review 3.  AMPK's double-faced role in advanced stages of prostate cancer.

Authors:  Faeze Gharibpoor; Sara Kamali Zonouzi; Sepideh Razi; Nima Rezaei
Journal:  Clin Transl Oncol       Date:  2022-07-04       Impact factor: 3.340

Review 4.  Emerging role of tumor cell plasticity in modifying therapeutic response.

Authors:  Siyuan Qin; Jingwen Jiang; Yi Lu; Edouard C Nice; Canhua Huang; Jian Zhang; Weifeng He
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

5.  Incidence of androgen receptor and androgen receptor variant 7 coexpression in prostate cancer.

Authors:  Jordan E Vellky; Tyler M Bauman; Emily A Ricke; Wei Huang; William A Ricke
Journal:  Prostate       Date:  2019-09-10       Impact factor: 4.104

Review 6.  Prostate Stem Cells and Cancer Stem Cells.

Authors:  Jia J Li; Michael M Shen
Journal:  Cold Spring Harb Perspect Med       Date:  2019-06-03       Impact factor: 6.915

Review 7.  Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis.

Authors:  Sukanya Basu; Yang Dong; Rahul Kumar; Collene Jeter; Dean G Tang
Journal:  Semin Cancer Biol       Date:  2021-05-09       Impact factor: 15.707

8.  High copy number variations, particular transcription factors, and low immunity contribute to the stemness of prostate cancer cells.

Authors:  Zao Dai; Ping Liu
Journal:  J Transl Med       Date:  2021-05-13       Impact factor: 5.531

9.  Prostate cancer-derived holoclones: a novel and effective model for evaluating cancer stemness.

Authors:  Louise Flynn; Martin P Barr; Anne-Marie Baird; Paul Smyth; Orla M Casey; Gordon Blackshields; John Greene; Stephen R Pennington; Emily Hams; Padraic G Fallon; John O'Leary; Orla Sheils; Stephen P Finn
Journal:  Sci Rep       Date:  2020-07-09       Impact factor: 4.379

Review 10.  The Etiology and Pathophysiology Genesis of Benign Prostatic Hyperplasia and Prostate Cancer: A New Perspective.

Authors:  Teow J Phua
Journal:  Medicines (Basel)       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.